Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study

Abstract

Background

The female genital tract constitutes a reservoir for HIV providing active production of both cell-free HIV RNA and cell-associated DNA within the cervicovaginal secretions. The objective of this study was to prospectively assess residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women initiating HAART over an 18-month period.

Methods

Paired blood and cervicovaginal lavage samples were collected at inclusion and 1, 6, 12 and 18 months after HAART initiation, in 23 women in first-line HAART and six women in virological failure, for measurement of HIV-1 RNA and HIV-1 DNA shedding and/or drug concentrations.

Results

A dramatic decrease of HIV-1 RNA and HIV-1 DNA occurred in both blood and cervicovaginal samples over the first 6 months on HAART, followed by a shelf up to 18 months, independently of the drugs’ genital pharmacokinetics. While cervicovaginal HIV-1 RNA became undetectable in >90% of women from 6 months on HAART, genital HIV-1 DNA remained frequently detectable (27–50%). Nearly 40% of women with sustained undetectable plasma HIV-1 RNA after 6–18 months on HAART harboured transient HIV-1 RNA (15% of women) or HIV-1 DNA (31% of women) in their genital secretions.

Conclusions

Low-level cervicovaginal HIV-1 shedding is frequently evidenced in HAART-treated women with transient HIV-1 RNA and persistent HIV-1 DNA despite a systemic control of viral replication, resulting in possible residual genital infectivity.

References

Coombs

R.W.

, Reichelderfer

P.S.

, Landay

A.L.

Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17: 455–480.

Kovacs

, Wasserman

S.S.

, Burns

Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358: 1593–1601.

Kemal

K.S.

, Foley

, Burger

HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003; 100: 12972–12977.

Kelley

C.F.

, Sullivan

S.T.

, Lennox

J.L.

, Evans-Strickfaden

, Hart

C.E.

Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women. AIDS 2010; 24: 1361–1366.

Hart

C.E.

, Lennox

J.L.

, Pratt-Palmore

Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179: 871–882.

Cu Uvin

, Caliendo

A.M.

, Reinert

S.E.

HIV-1 in the female genital tract and the effect of antiretroviral therapy. AIDS 1998; 12: 826–827.

Cu-Uvin

, Caliendo

A.M.

, Reinert

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14: 415–421.

Si-Mohamed

, Kazatchkine

M.D.

, Heard

Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000; 182: 112–122.

Kwara

, Delong

, Rezk

Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46: 719–725.

10.

Fiore

J.R.

, Suligoi

, Saracino

Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17: 2169–2176.

11.

Cu-Uvin

, Snyder

, Harwell

J.I.

Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42: 584–587.

12.

Neely

M.N.

, Benning

, Xu

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44: 38–42.

13.

Graham

S.M.

, Holte

S.E.

, Peshu

N.M.

Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21: 501–507.

14.

Kemal

K.S.

, Burger

, Mayers

HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007; 195: 535–545.

15.

Hawes

S.E.

, Sow

P.S.

, Stern

J.E.

Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22: 2517–2525.

16.

Nagot

, Ouedraogo

, Weiss

H.A.

Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect 2008; 84: 167–170.

17.

Cu-Uvin

, Delong

A.K.

, Venkatesh

K.K.

Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24: 2489–2497.

18.

Castilla

, Del Romero

, Hernando

Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40: 96–101.

19.

Quinn

T.C.

, Wawer

M.J.

, Sewankambo

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921–929.

20.

Gray

R.H.

, Wawer

M.J.

, Brookmeyer

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149–1153.

21.

Vernazza

P.L.

The debate continues: does ‘undetectable’ mean ‘uninfectious'?

HIV Ther 2009; 3: 113–116.

22.

Vernazza

, Hirschel

, Bernasconi

, Flepp

[HIV-infected individuals without additional STD and on effective antiretroviral therapy are not sexually infectious]. Schweizerische Ärztezeitung 2008; 89: 165–169. German.

23.

Yeni

P.G.

, Hammer

S.M.

, Hirsch

M.S.

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society – USA Panel. JAMA 2004; 292: 251–265.

24.

Launay

, Tod

, Louchahi

Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004; 48: 632–634.

25.

Bélec

, Meillet

, Levy

Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol 1995; 2: 57–61.

26.

Legoff

, Bouhlal

, Gresenguet

Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol 2006; 44: 423–432.

27.

Pasquier

, Millot

, Njouom

HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94: 45–54.

28.

Bouley

, Briere

, Padoin

Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 2001; 23: 56–60.

29.

Jacqmin-Gadda

, Thiebaut

, Chene

, Commenges

Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 2000; 1: 355–368.

30.

Beal

A.D.

, Ludden

, Boeckmann

NONMEM users guide. Version VI. Ellicot City, MD: GloboMax, ICON Development Solutions 2006.

31.

Karlsson

M.O.

, Sheiner

L.B.

The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735–750.

32.

Karlsson

M.O.

, Savic

R.M.

Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17–20.

33.

Brendel

, Comets

, Laffont

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23: 2036–2049.

34.

Iversen

A.K.

, Larsen

A.R.

, Jensen

Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177: 1214–1220.

35.

Nuovo

G.J.

, Forde

, MacConnell

In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol 1993; 143: 40–48.

36.

Bardeguez

A.D.

, Skurnick

J.H.

, Perez

Lymphocyte shedding from genital tract of human immunodeficiency virus-infected women: immunophenotypic and clinical correlates. Am J Obstet Gynecol 1997; 176: 158–165.

37.

Andréoletti

, Chomont

, Grésenguet

Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis 2003; 188: 549–554.

38.

D.D.

, Neumann

A.U.

, Perelson

A.S.

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–126.

39.

Bruisten

S.M.

, Reiss

, Loeliger

A.E.

Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998; 14: 1053–1058.

40.

Di Mascio

, Markowitz

, Louie

Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77: 12165–12172.

41.

Marcelin

A-G

, Tubiana

, Lambert-Niclot

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. 16th Conference on Retroviruses and Opportunistic infections (CROI). 8–11 February 2009, Montréal, QC, Canada. Abstract 51.

42.

Mbopi-Kéou

F.X.

, Grésenguet

, Mayaud

Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182: 1090–1096.

43.

Witteck

, Yerly

, Vernazza

Unusually high HIV infectiousness in an HIV-, HCV- and HSV-2-coinfected heterosexual man. Swiss Med Wkly 2009; 139: 207–209.

44.

Sha

B.E.

, Zariffard

M.R.

, Wang

Q.J.

Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005; 191: 25–32.

45.

Zara

, Nappi

R.E.

, Brerra

Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex Transm Infect 2004; 80: 108–112.

46.

Tuomala

R.E.

, O'Driscoll

P.T.

, Bremer

J.W.

Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187: 375–384.

47.

Sallé

, Brochard

, Bourry

Infection of macaques after vaginal exposure to cell associated simian immunodeficiency virus. J Infect Dis 2010; 202: 337–344.

48.

Zhu

, Wang

, Carr

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70: 3098–3107.

49.

Ellerbrock

T.V.

, Lennox

J.L.

, Clancy

K.A.

Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001; 184: 28–36.

50.

Ongradi

, Ceccherini-Nelli

, Pistello

, Specter

, Bendinelli

Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990; 6: 1433–1436.

51.

Cohen

AIDS research. Treat everyone now? A ‘radical’ model to stop HIV's spread. Science 2008; 322: 1453.